Sym004, a Novel EGFR Antibody Mixture, Can Overcome Acquired Resistance to Cetuximab

The epidermal growth factor receptor (EGFR) is a central regulator of tumor progression in a variety of human cancers. Cetuximab is an anti-EGFR monoclonal antibody that has been approved for head and neck and colorectal cancer treatment, but many patients treated with cetuximab don't respond o...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Iida, Mari, Brand, Toni M, Starr, Megan M, Li, Chunrong, Huppert, Evan J, Luthar, Neha, Pedersen, Mikkel W, Horak, Ivan D, Kragh, Michael, Wheeler, Deric L
Materialtyp: Artigo
Språk:Inglês
Publicerad: Neoplasia Press Inc. 2013
Ämnen:
Research Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3819635/
https://ncbi.nlm.nih.gov/pubmed/24204198
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk